Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4059-14 relative bioavailability study in healthy Japanese males
jRCT2071230119Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tirabrutinib in primary central nervous system lymphoma (PCNSL), Waldenström macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL) (4 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Relative bioavailability. Started Mar 2024; status: completed.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on jRCT2071230119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230119.